Coherus shares fell 21.6% after earnings, as investors appear to have focused on the company’s need to sharply reduce costs and its reliance on growing LOQTORZI revenue to cover core cash burn. Management plans a 30% headcount reduction and narrowed tagmokitug development to esophageal cancer, but the transcript does not provide evidence that LOQTORZI has yet reached the revenue level needed to support the business.
Coherus Oncology shares rose 11.4% post-earnings as clinical trial progress and clear data timing on key pipeline assets notably outperformed expectations, supporting confidence in upcoming catalysts and commercial execution.
Coherus Oncology reported strong Q3 2025 results, demonstrating significant progress in both financial metrics and clinical development, particularly with its promising pipeline of cancer therapies.